Evaluation of efficacy and safety of ASPURUS for management of menopausal symptoms (Hot Flushes, Anxiety, Stress, Sleep etc.,) and Regulation of HPO axis: A prospective, randomized, double-blind, multi center, placebo-controlled, interventional study - NI

Waleria Healthtech Pvt. Ltd.,0 个研究点目标入组 0 人开始时间: 待定最近更新: 2023年9月18日

试验速览

暂无简介。

•1.Female subjects aged 40 years to 65 years .
•2.Subjects who are experiencing menopausal symptoms such as hot flushes, night sweats, anxiety, depression, insomnia etc., as diagnosed by the study investigator.
•3.Subjects who are otherwise healthy except for the menopausal symptoms.
•4.Subjects or their legally acceptable representative are willing to provide informed written consent and agree to adhere to the study procedures.

•1.Pregnant, planning to become pregnant or breastfeeding women.
•2.Subjects who have undergone partial or complete hysterectomy
•3.Subjects who are undertaking hormone replacement therapy or any other herbal medicine treatment for menopausal symptoms.
•4.Current or history of a serious illnesses in the last three months which as per the study investigator will impact the study outcomes.
•5.History of or current Alcohol or substance abuse
•6.Allergy or sensitivity to any of the ingredients in the study treatment
•7.Subjects who have participated in other clinical studies during the past 3 months or subjects who intend to participate in other clinical studies parallelly.
•8.Subjects with any other illness or health condition which in the opinion/medical judgement of the study investigator makes the subject ineligible to participate in the study.

发起方

Waleria Healthtech Pvt. Ltd.,